Waldenström macroglobulinemia and relationship to immune deficiency.

Autor: Levy A; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Guidez S; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Debiais C; Laboratoire d'Anatomie Pathologie, CHU, Poitiers, France., Princet I; Pharmacie Centrale, CHU, Poitiers, France., Bouyer S; Service d'Hématologie Biologique, CHU, Poitiers, France., Dindinaud E; Service d'Hématologie Biologique, CHU, Poitiers, France., Delwail V; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Systchenko T; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Moya N; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Gruchet C; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Sabirou F; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Bobin A; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Gardeney H; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Nsiala L; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Cailly L; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Olivier G; Service de Médecine Interne, Niort, France., Motard C; Service de Médecine Interne, Niort, France., Fleck E; Service d'Onco-Hématologie, La Rochelle, France., Corby A; Service d'Onco-Hématologie, La Rochelle, France., Roul C; Service d'Onco-Hématologie, La Rochelle, France., Denis G; Service de Médecine Interne, Rochefort, France., Dieval C; Service de Médecine Interne, Rochefort, France., Leleu X; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France., Tomowiak C; Service d'Hématologie et Thérapie Cellulaire, CHU and Inserm, Poitiers, France.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2021 Nov; Vol. 62 (11), pp. 2665-2670. Date of Electronic Publication: 2021 Jun 04.
DOI: 10.1080/10428194.2021.1907379
Abstrakt: Primary or secondary immune deficiency (ID) is a risk factor, although rare, to develop Waldenström macroglobulinemia (WM). We aimed to better understand the incidence of this occurrence in the real-life and the outcome of either entity. We conducted a review of 194 WM in the Poitou-Charentes registry and identified 7 (3.6%) with a prior history of ID. Across the 7 WM with ID, 4 progressed to active WM disease and required treatment for WM with a median time between WM diagnosis and the first treatment of 1.5 years (range 0-3). The median time from ID to WM occurrence was 8 years (1-18). WM could develop from ID, although a rare event. Our first action was to systematically decrease immunosuppression with long-term control of ID. Half of indolent WM remained indolent despite ID and for remaining WM none appeared of poor risk WM.
Databáze: MEDLINE
Externí odkaz: